These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9589244)

  • 21. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients.
    Rave K; Heinemann L; Puhl L; Gudat U; Woodworth JR; Weyer C; Heise T
    Diabetes Care; 1999 May; 22(5):865-6. PubMed ID: 10332707
    [No Abstract]   [Full Text] [Related]  

  • 23. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
    Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T
    Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin.
    ter Braak EW; Woodworth JR; Bianchi R; Cerimele B; Erkelens DW; Thijssen JH; Kurtz D
    Diabetes Care; 1996 Dec; 19(12):1437-40. PubMed ID: 8941480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.
    Rave K; Heise T; Pfützner A; Heinemann L; Sawicki PT
    Diabetes Care; 2001 May; 24(5):886-90. PubMed ID: 11347749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
    von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.
    Rave K; Bott S; Heinemann L; Sha S; Becker RH; Willavize SA; Heise T
    Diabetes Care; 2005 May; 28(5):1077-82. PubMed ID: 15855570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes.
    Heise T; Bott S; Rave K; Dressler A; Rosskamp R; Heinemann L
    Diabet Med; 2002 Jun; 19(6):490-5. PubMed ID: 12060061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmaceutical development and clinical experiment of new antidiabetic drugs, premixed preparations of insulin lispro (Humalog Mix 25 and Humalog Mix 50) and intermediate-acting insulin lispro (Humalog N)].
    Awa T; Nakata T; Shigeta H
    Nihon Yakurigaku Zasshi; 2005 Aug; 126(2):143-51. PubMed ID: 16205018
    [No Abstract]   [Full Text] [Related]  

  • 34. A novel insulin formulation with a more rapid onset of action.
    Steiner S; Hompesch M; Pohl R; Simms P; Flacke F; Mohr T; Pfützner A; Heinemann L
    Diabetologia; 2008 Sep; 51(9):1602-6. PubMed ID: 18641968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects.
    Homko C; Deluzio A; Jimenez C; Kolaczynski JW; Boden G
    Diabetes Care; 2003 Jul; 26(7):2027-31. PubMed ID: 12832307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL.
    de la Peña A; Seger M; Soon D; Scott AJ; Reddy SR; Dobbins MA; Brown-Augsburger P; Linnebjerg H
    Clin Pharmacol Drug Dev; 2016 Jan; 5(1):69-75. PubMed ID: 27119580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.
    Heinemann L; Weyer C; Rauhaus M; Heinrichs S; Heise T
    Diabetes Care; 1998 Nov; 21(11):1910-4. PubMed ID: 9802742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight.
    Mohn A; Matyka KA; Harris DA; Ross KM; Edge JA; Dunger DB
    Diabetes Care; 1999 Jan; 22(1):27-32. PubMed ID: 10333899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
    Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
    Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.